MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Long-Term Neuropsychological Outcomes of Deep Brain Stimulation in Early-Stage Parkinson’s Disease

    M. Hacker, M. Tramontana, J. Meystedt, M. Turchan, K. Harper, B. Eoff, R. Fan, F. Ye, T. Davis, P. Konrad, D. Charles (Nashville, USA)

    Objective: To report long-term (5-year and 11-year) neuropsychological outcomes from the deep brain stimulation (DBS) in early-stage Parkinson’s disease (PD) pilot clinical trial. Background: The…
  • 2022 International Congress

    Updated Parkinson’s disease motor subtypes classification and correlation to CSF HVA and 5-HIAA levels

    M. Schiess, J. Suescun, A. Haque, K. Block, E. Tharp, T. Ellmore, C. Adams (Houston, USA)

    Objective: To update a motor subtypes classification using the MDS-UPDRS and determine if CSF neurotransmitter profiles (HVA and 5-HIAA) are different between MDS-UPDRS subtypes in…
  • 2022 International Congress

    Functional MRI and gait analysis characteristics in patients with idiopathic rem sleep behavior disorder

    E. Sarasso, A. Gardoni, S. Marelli, L. Zenere, A. Castelnuovo, A. Tettamanti, L. Ferini-Strambi, M. Filippi, F. Agosta (Milano, Italy)

    Objective: The aims of this study were to assess gait analysis, neurological, neuropsychological and resting-state functional MRI (RS-fMRI) functional connectivity (FC) characteristics in iRBD patients…
  • 2022 International Congress

    Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort

    T. Simuni, K. Merchant, M. Brumm, C. Caspell-Garcia, H. Cho, C. Coffey, L. Chahine, A. Siderowf, C. Tanner, K. Marek, P. Investigators (Chicago, USA)

    Objective: To examine 2-year longitudinal change in clinical, dopamine transporter (DAT) imaging and biofluid biomarkers in non-manifesting carriers (NMCs) of LRRK2 G2019S versus healthy controls…
  • 2022 International Congress

    Longitudinal study of Parkinson’s disease-related pattern with resting state functional MRI

    A. Vo, N. Nguyen, D. Eidelberg (Manhasset, USA)

    Objective: To validate the previously characterized resting-state fMRI (rs-fMRI) Parkinson’s disease (PD)-related pattern, termed fPDRP, in a large multi-site PD imaging database, and to assess…
  • 2022 International Congress

    P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial

    C. Olanow, K. Kieburtz, P. Litman, H. Friedman, S. Oren (Sarasota, USA)

    Objective: Evaluate the efficacy and safety of P2B001 compared with its components and with Extended-Release pramipexole (ER-PPX, calibration arm) in untreated PD. Background: P2B001 is…
  • 2022 International Congress

    Postural Instability in Parkinson’s Disease: Phenotypic data from The Cincinnati Cohort Biomarker Program

    K. Duque, J. Abanto, R. Bode, N. Gregor, F. Pariona, J. Hernandez, A. Espay, L. Marsili (Cincinnati, USA)

    Objective: To estimate the onset of postural instability in a cohort of Parkinson's disease (PD) patients. Background: The Cincinnati Cohort Biomarker Program (CCBP), launched in…
  • 2022 International Congress

    Caregiving patients with Parkinson disease treated with deep brain stimulation: a systematic review and meta-synthesis of qualitative research

    V. Fioravanti, F. Cavallieri, F. Sireci, M. Parmeggiani, C. Pedroni, F. Mardones, M. Bassi, E. Moro, L. Ghirotto, F. Valzania (Reggio Emilia, Italy)

    Objective: To explore the experiences and unmet needs of Parkinson disease patients (PDPs) caregivers after subthalamic nucleus deep brain stimulation (STN-DBS) by performing a systematic…
  • 2022 International Congress

    Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study

    S. Joza, M. Hu, KY. Jung, D. Kunz, P. Dusek, D. Arnaldi, B. Högl, L. Ferini-Strambi, M. Terzaghi, F. Sixel-Döring, M. Puligheddu, F. Provini, S. Lewis, J. Liu, J. Bušková, A. Nicoletti, Y. Dauvilliers, C. Bassetti, M. Lawton, HJ. Kim, JS. Sunwoo, F. Bes, K. Sonka, P. Mattioli, A. Stefani, A. Ibrahim, G. Fiamingo, B. Mollenhauer, C. Trenkwalder, M. Figorilli, P. Cortelli, L. Baldelli, K. Ehgoetz Martens, Y. Li, E. Cicero, L. Guiraud, C. Schaefer, A. Pelletier, R. Postuma (Montreal, Canada)

    Objective: To inform the design of randomized neuroprotective trials in prodromal Parkinson’s disease (PD) by assessing the progression of prodromal markers in idiopathic rapid eye…
  • 2022 International Congress

    Association between dihydropyridines and dementia conversion in Parkinson’s disease

    JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

    Objective: To investigate the role of antihypertensive drugs, including dihydropyridines, on nigrostriatal dopamine and dementia conversion in Parkinson's disease Background: Several experimental and clinical studies…
  • « Previous Page
  • 1
  • …
  • 103
  • 104
  • 105
  • 106
  • 107
  • …
  • 153
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley